Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

Breast

Volumn 21, Issue 3, 2012, Pages 336-342

  Galardi, Francesca ^a   Oakman, Catherine ^a   Truglia, Maria Caterina ^a   Cappadona, Silvia ^a   Biggeri, Annibale ^b   Grisotto, Laura ^b   Giovannelli, Lisa ^b   Bessi, Silvia ^a   Giannini, Augusto ^a   Biganzoli, Laura ^a   Santarpia, Libero ^a   Di Leo, Angelo ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Breast cancer; Comet assay; DNA damage; Single cell gel electrophoresis

Indexed keywords

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER TISSUE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 84862513854     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.02.007     Document Type: Article

References (26)

1. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
2. Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123:236-240.
3. Asakawa H., Koizumi H., Koike A., Takahashi M., Wu W., Iwase H., et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010, 12:R17.
4. Alexander B.M., Sprott K., Farrow D.A., Wang X., D'Andrea A.D., Shnitt S.J., et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010, 16:5796-5804.
5. Graeser M., McCarthy A., Lord C.J., Savage K., Hills M., Salter J., et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010, 16:6159-6168.
6. Rodriguez A.A., Makris A., Wu M.F., Rimawi M., Frohelich A., Dave B., et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010, 123:189-196.
7. Collins A.R. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004, 26:249-261.
8. Langie S.A., Knaapen A.M., Brauers K.J., van Berlo D., van Schooten F.J., Godschalk R.W., et al. Development and validation of a modified comet assay to phenotipically assess nucleotide excision repair. Mutagenesis 2006, 21:153-158.
9. Gaivao I., Piasek A., Brevik A., Shaposhnikov S., Collins A.R. Comet assay based methods for measuring DNA repair in vitro; estimates of inter- and intra-individual variation. Cell Biol Toxicol 2009, 25:45-52.
10. Collins A.R., Oscoz A.A., Brunborg G., Gaivão I., Giovannelli L., Kruszewski M., et al. The comet assay: topical issues. Mutagenesis 2008, 23:143-151.
11. Wozniak K., Kolacinska A., Blasinska-Morawiec M., Morawiec-Bajda A., Morawiec Z., Zadrozny M., et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007, 81:519-527.
12. Leong C.O., Suggitt M., Swaine D.J., Bibby M.C., Stevens M.F., Bradshaw T.D. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 2004, 3:1565-1575.
13. Blasiak J., Arabski M., Krupa R., Wozniak K., Rykala J., Kolacinska A., et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 2004, 554:139-148.
14. Rajeswari N., Ahuja Y.R., Malini U., Balakrishna N., Rao K.V., Khar A., et al. Risk assessment in first degree female relatives of breast cancer patients using the alkaline comet assay. Carcinogenesis 2000, 21:557-561.
15. Herrera M., Dominiguez G., Garcia M.J., Peña C., Jimenez C., Silva J., et al. Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 2009, 15:5466-5472.
16. Cuzick J., Dowsett M., Pineda S., Wale C., Salter J., Quinn E., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011, 29:4273-4278.
17. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
18. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
19. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
20. Tan D.S., Marchió C., Jones R.L., Savage K., Smith I.E., Dowsett M., et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111:27-44.
21. Turner N., Lambros M.B., Horlings H.M., Pearson A., Sharpe R., Natrajan R., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023.
22. Barry W.T., Kernagis D.N., Dressman H.K., Griffis R.J., Hunter J.D., Olson J.A., et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 2010, 28:2198-2206.
23. Miller D.V., Jenkins R.B., Lingle W.L., Davidson N.E., Kaufman P.A., Martino S., et al. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004, 22:14s. [abstr 568].
24. Smith C.C., O'Donovan M.R., Martin E.A. HOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 2006, 21:185-190.
25. Chen G., Chang J.-L., Lampe J.W., Ulrich C.M. Reproducibility study of DNA damage measurement by the comet assay. Proc Am Assoc Cancer Res 2004, 45. [abstract 3163].
26. McGlynn A.P., Wasson G.R., O'Reilly S., McKelvey-Martin V.J., McNulty H., Strain J.J., et al. Detection of replicative integrity in small colonic biopsies using the BrdUrd comet assay. Br J Cancer 2003, 88:895-901.